Wei Ding, MD
Hematology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Office
- 1
Offices
1 location
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Ding’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
Drugs they prescribed that Part D paid
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their 143 Part D prescriptions in 2023.
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
Year by year
| 2023 | 143 | 31 | 0% (0) | 69% | $1,126,692 |
| 2022 | 256 | 47 | 0% (0) | 61% | $1,671,071 |
| 2021 | 266 | 45 | 0% (0) | 39% | $1,233,873 |
| 2020 | 279 | 40 | 0% (0) | 33% | $814,325 |
| 2019 | 168 | 30 | None | 38% | $583,698 |
| 2018 | 129 | 25 | None | 61% | $671,730 |
| 2017 | 89 | 18 | None | 35% | $245,533 |
| 2016 | 47 | 12 | 0% (0) | 51% | $192,134 |
| 2015 | 55 | None | None | 42% | $169,292 |
| 2014 | 32 | None | None | None | $47,610 |
| 2013 | 11 | None | 0% (0) | None | $377 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Calquence | 56 | $773,508 | $13,813 |
| Venclexta | 24 | $293,936 | $12,247 |
| Acyclovir | 21 | $669 | $32 |
| Sulfamethoxazole-Trimethoprim | 12 | $152 | $13 |
2022: 6 drugs
| Calquence | 81 | $951,201 | $11,743 |
| Calquence | 23 | $304,960 | $13,259 |
| Venclexta | 21 | $209,107 | $9,957 |
| Imbruvica | 26 | $190,815 | $7,339 |
| Acyclovir | 47 | $1,411 | $30 |
| Sulfamethoxazole-Trimethoprim | 19 | $275 | $14 |
2021: 6 drugs
| Calquence | 58 | $719,598 | $12,407 |
| Imbruvica | 30 | $385,309 | $12,844 |
| Fluconazole | 13 | $1,805 | $139 |
| Acyclovir | 40 | $1,329 | $33 |
| Sulfamethoxazole-Trimethoprim | 55 | $434 | $8 |
| Allopurinol | 21 | $178 | $8 |
2020: 6 drugs
| Calquence | 29 | $370,608 | $12,780 |
| Imbruvica | 29 | $315,918 | $10,894 |
| Venclexta | 18 | $88,426 | $4,913 |
| Acyclovir | 69 | $1,603 | $23 |
| Sulfamethoxazole-Trimethoprim | 50 | $325 | $6 |
| Allopurinol | 21 | $165 | $8 |
2019: 4 drugs
| Imbruvica | 50 | $523,881 | $10,478 |
| Acyclovir | 40 | $944 | $24 |
| Allopurinol | 13 | $172 | $13 |
| Sulfamethoxazole-Trimethoprim | 27 | $137 | $5 |
2018: 3 drugs
| Imbruvica | 56 | $548,496 | $9,795 |
| Acyclovir | 11 | $294 | $27 |
| Sulfamethoxazole-Trimethoprim | 15 | $156 | $10 |
2017: 2 drugs
| Imbruvica | 25 | $229,860 | $9,194 |
| Sulfamethoxazole-Trimethoprim | 15 | $126 | $8 |
2016: 1 drug
| Imbruvica | 18 | $184,939 | $10,274 |
2015: 1 drug
| Imbruvica | 19 | $145,316 | $7,648 |
Money from drug and device companies
$11 in 2022
| 2022 | 1 | 1 | None | $11 |
| 2020 | 1 | 2 | $1,950 | $1,950 |
| 2019 | 2 | 5 | $3,500 | $4,650 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Merck Sharp & Dohme | Keytruda | $11 | 1 payment
|
See the published payment
| Merck Sharp & Dohme | Education · 2022-01-28 | Keytruda | $11 |
See earlier years (2020, 2019)
2020: $1,950
| BeiGene USA | Brukinsa | $1,950 | 2 payments
|
2019: $4,650
| Octapharma USA | Octagam Immune Globulin (Human) | $4,555 | 4 payments
|
| Verastem | Copiktra | $94 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · Phase II Study of A Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab (Medi4736) in Patients With Richter Transformation From Chronic Lymphocytic Leukemia (Cll) · 2023 | Their institution | $640,240 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Anti-Pd-1 Antibody Mk-3475 in Relapsed,Refractory Chronic Lymphocytic Leukemia Cll and Other Low Grade B Cell Non-Hodgkin Lymphoma Nhl · 2019 | Their institution | $595,235 |
| AstraZeneca Pharmaceuticals LP · Phase II Study of A Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab (Medi4736) in Patients With Richter Transformation From Chronic Lymphocytic Leukemia (Cll) · 2024 | Their institution | $405,986 |
| BeiGene, Ltd. · A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor Bgb-11417 in Patients With Mature B-Cell Malignancies · 2023 | Their institution | $403,824 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Anti-Pd-1 Antibody Mk-3475 in Relapsed,Refractory Chronic Lymphocytic Leukemia Cll and Other Low Grade B Cell Non-Hodgkin Lymphoma Nhl · 2021 | Their institution | $260,308 |
| Merck Sharp & Dohme LLC · Study Name#Role of Regulatory T Cells in Mediating Clinical Responses of Richter Patients Treated With Pembrolizumab · 2023 | Their institution | $238,882 |
| BeiGene AUS Pty Ltd · A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor Bgb-11417 in Patients With Mature B-Cell Malignancies · 2023 | Their institution | $233,757 |
| AstraZeneca Pharmaceuticals LP · Phase II Study of A Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab (Medi4736) in Patients With Richter Transformation From Chronic Lymphocytic Leukemia (Cll) · 2022 | Their institution | $230,468 |
| Merck Sharp & Dohme LLC · Role of Regulatory T Cells in Mediating Clinical Responses of Richter Patients Treated With Pembrolizumab · 2022 | Their institution | $179,162 |
| Merck Sharp & Dohme Corporation · Study Nameextended the Grant To Align With the Payment Schedule. · 2021 | Their institution | $141,416 |
| Merck Sharp & Dohme LLC · Study Name#Role of Regulatory T Cells in Mediating Clinical Responses of Richter Patients Treated With Pembrolizumab · 2024 | Their institution | $119,441 |
| BeiGene, Ltd. · A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader Bgb-16673 in Patients With B-Cell Malignancies · 2023 | Their institution | $69,026 |
| BeiGene AUS Pty Ltd · A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor Bgb-11417 in Patients With Mature B-Cell Malignancies · 2024 | Their institution | $66,923 |
| Octapharma USA, Inc. · Ngam-12 · 2022 | Their institution | $35,814 |
| Octapharma USA, Inc. · Ngam-12 · 2021 | Their institution | $31,940 |
| AbbVie Inc. · Venclexta · 2020 | Their institution | $31,888 |
| ABBVIE INC. · A Prospective, Open-Label, Single-Arm, Phase 2, Multicenter Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-Cell Prolymphocytic Leukemia · 2021 | Their institution | $10,927 |
| BeiGene, Ltd. · A Phase 1, Open-Label, Dose Escalation and Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader Bgb-16673 in Patients With B Cell Malignancies · 2022 | Their institution | $9,720 |
| ABBVIE INC. · A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Participants With T-Cell Prolymphocytic Leukemia · 2022 | Their institution | $9,007 |
| Octapharma USA, Inc. · Ngam12 · 2023 | Their institution | $8,850 |
| Merck Sharp & Dohme LLC · A Phase II Study of Pembrolizumab Mk-3475 in Subjects With Relapsed Or Refractory Primary Mediastinal Large B-Cell Lymphoma Rrpmbcl Or Relapsed Or Refractory Richter Syndrome Rrrs · 2023 | Their institution | $7,487 |
Professional record
- NPI
- 1265454201
- Licence
- MN 48601
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0000X (207RH0000X); Medical oncology (207RX0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-07-25
- NPI last updated
- 2025-04-29
- NPI record certified
- 2025-04-29
This is when the NPI record was last certified, not a medical board exam.